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On the Cover 
Left: Physician Mina Pastagia, a Clinical 
Scholar who is studying a novel treatment 
for staphylococcal skin infections in 
psoriasis patients. 
Center: Virologist Charles Rice, a leader in 
the study of hepatitis C, with postdoctoral 
investigator Catherine Murray. 
Right: Melissa Offenhartz (at left), director 
of nursing and patient care services, and 
nursing assistant Olga Ford. 
A .REVOLUTIONARY IDEA 
For more than a century, The Rockefeller University has stood at the 
forefront of biomedical discovery. Founded in 1901 as the nation's first 
medical research center, Rockefeller has long been a world leader in the 
effort to understand human health and 
disease. Rockefeller's research hospital, 
which opened its doors in 1910, was the 
country's first clinical research hospital­
and the birthplace of clinical research in the 
United States. A hospital unlike any other at 
the time, this facility was devoted to clinical 
investigation and to translating laboratory 
discoveries into new approaches to diag­
nosing, treating, and preventing disease. 
The revolutionary idea on which the 
Hospital was founded is as alive today 
as it was in 1910. The rise of molecular 
biology, born in the Rockefeller Hospital 
in 1944, has opened previously unimagined 
therapeutic possibilities. Thus, translating 
basic discoveries into medical treatments 
and preventions is more important than 
ever. More and more, both basic scientists and physician-scientists are 
exploring medical applications of their discoveries. The Hospital's expert 
and dedicated staff and I are doing all we can to support the efforts of 
these gifted investigators and to train the next generation of clinical 
research leaders. 
Barry S. Coller, M.D. 
Physician-in-Chief 
The Rockefeller University Hospital 
EXTRAORDINARY BREAKTHROUGHS 
The Rockefeller Hospital has been the site of myriad breakthroughs that 
have advanced the treatment and prevention of disease, including the 
discovery that DNA is the carrier of genetic information-the finding 
that launched the modern biological revolution. Rockefeller researchers 
were also the first to: 
• demonstrate that a virus can cause cancer
• confirm the connection between cholesterol and heart disease
• create effective vaccines for meningitis and pneumonia
• develop animal models for the study of heart disease and
multiple sclerosis
• discover blood types and ways to preserve whole blood, making
blood banks possible
• pioneer clinical studies based on the dendritic cell, a key immune
system cell discovered at Rockefeller
• demonstrate that the body's metabolism adjusts to maintain a set
weight, helping to explain why weight loss is so difficult
• develop drug combinations that offered the first life-extending
treatments for HIV and AIDS
• discover an obesity gene and a weight-regulating hormone, leptin
• devise methadone treatment to manage heroin addiction
• develop a rationally designed antiplatelet therapy, which improved
the results of coronary artery stenting
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Above: The Rockefeller University Hospital, 
which has been extensively renovated 
over the past decade, houses a 20-bed 
inpatient unit and an outpatient center, as 
well as state-of-the-art laboratories for 
principal investigators. 
Right: World-renowned AIDS investigator 
David Ho administers a new vaccine under 
study to a volunteer at the Hospital. 
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LEADING THE WAY IN CLINICAL RESEARCH 
AND MOLECULAR MEDICINE 
Biomedical scientists associated with the Hospital conduct research that is 
innovative and influential. They are creating new "smart" drugs, designing 
and testing therapeutic and preventative vaccines, and introducing a host 
of other medical interventions that emanate from the latest laboratory 
findings. Working at the cutting edge of molecular medicine and clinical 
investigation, the University's researchers are developing: 
• Precise molecular markers that can be used to plan cancer treatment,
based on a Rockefeller scientist's discovery of several microRNAs
that disable tumor metastasis. MicroRNAs, tiny molecular entities
that were unknown 20 years ago, are now recognized as determi­
nants of health and disease.
• New methods using microRNAs to identify disease-relevant genetic
variations in individuals with fragile X syndrome, which is strongly
associated with _autism. These technologies will eventually contribute
to custom-designed treatments for a range of disorders.
• A "nanosyringe" for intracellular delivery of protein therapeutics,
re-engineered from a mechanism that some bacteria use to inject
toxins into host cells.
• New ways to prevent and treat rare childhood infections as well as
global diseases such as tuberculosis, based on a Rockefeller scien­
tist's revolutionary work that is revealing inborn immune deficien­
cies that confer vulnerability to specific microorganisms.
• New ways to fight MRSA and other antibiotic-resistant bacteria with
an enzyme isolated from a phage-a virus that kills bacteria. This
could dramatically reduce the incidence of resistant infections
acquired in hospitals, a leading cause of death in the elderly.
• New therapeutic regimens for melanoma based on knowledge
acquired from state-of-the-art molecular genetic and imaging studies.
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• Recommendations regarding the effectiveness of vitamin D in
preventing cardiovascular disease.
• A broad-spectrum therapy to suppress autoimmunity, the harmful
attack by the immune system against the body's own cells that can
result in rheumatoid arthritis, type 1 diabetes, and lupus.
Right: The Hospital's nursing staff plays an 
essential role in clinical investigations. 
Below: Physician-scientist Agata 
Smogorzewska with a member of her 
laboratory. A Rockefeller alumna, she 




The Clinical Scholars Program at The Rockefeller University Hospital 
addresses one of the most pressing needs in biomedicine: the training of 
physician-scientists who are qualified to conduct research in both the 
laboratory and the clinic. The three-year program is designed to provide 
an optimal environment and mentoring structure in which young physi­
cians gain the experience and capabilities necessary to initiate indepen­
dent careers as patient-oriented and translational investigators. 
Most applicants to the program are physicians who have recently com­
pleted their residency or subspecialty fellowship. Each Clinical Scholar 
becomes affiliated with at least 
one Rockefeller research group 
and carries out patient-oriented 
translational research under 
the mentorship of the head of 
laboratory. This independent 
research is complemented by a 
rigorous core curriculum in 
clinical and translational inves­
tigation. The program leads to 
a master's degree in clinical and 
translational research. 
Current and recent Clinical 
Scholars conduct or have con­
ducted innovative biological 
research on a broad spectrum 
of medical problems, includ-
ing tumor immunity and 
tumor immunotherapy, the regulation of dietary cholesterol absorption, 
platelet physiology and thrombosis, the autoimmune basis of psoriasis, 
the role of the hormone leptin in obesity, HIV infection and treatment, 
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the development of vaccines for HIV, immune dysregula<tion associated 
with hepatitis C, the molecular and genetic bases of addiction, and a 
range of questions in basic immunology. 
Although most Clinical Scholars are associated with Hospital-based 
laboratories, several Scholars have joined basic research groups to initi­
ate and carry out projects that integrate recent findings in biology with 
patient-based studies. Topics addressed by these Clinical Scholars in-
Left: Clinical Scholar Dana Orange with Robert Darnell, head 
of the Laboratory of Molecular Neuro-oncology. 
Below: Immunologist Marina Caskey (at right) with colleagues. 
A former Clinical Scholar, Dr. Caskey continues to conduct HIV 
vaccine research at Rockefeller under a career development 
award from the National Institutes of Health. 
clude liver inflammation, the 
cause of chronic lymphocytic 
leukemia and lymphomas, and 
the application of RNA biology 
to kidney disease and neurode-
generative disorders. 
DISTINGUISHED FACULTY 
Faculty currently affiliated with the Rockefeller Hospital include such 
outstanding investigators as: 
Jan L. Breslow, M.D., former president of the American Heart 
Association, who has pioneered the use of DNA technology to study 
heart disease. 
Senior Attending Physician, Frederick Henry Leonhardt Professor 
Laboratory of Biochemical Genetics and Metabolism 
Jean-Laurent Casanova, M.D., Ph.D., who received the 2008 Richard 
Lounsbery Award for discoveries about genetic vulnerabilities to viral 
and bacterial diseases of childhood. 
Senior Attending Physician, Professor 
St. Giles Laboratory of Human Genetics of Infectious Diseases 
Barry S. Coller, M.D., a leader in vascular biology, who developed an 
F.D.A. approved antiplatelet therapy and created a test to monitor the
effectiveness of aspirin and clopidogrel (Plavix) in individual patients.
Physician-in-Chief, Vice President for Medical Affairs 
David Rockefeller Professor 
Allen and Frances Adler Laboratory of Blood and Vascular Biology 
Robert B. Darnell, M.D., Ph.D., whose work is shedding light on 
autoimmunity, neurodegenerative diseases, and cancer. 
Senior Attending Physician, Robert and Harriet Heilbrunn Professor 
Laboratory of Molecular Neuro-oncology 
Investigator, Howard Hughes Medical Institute 
Vincent A. Fischetti, Ph.D., who is developing novel antibacterial 
strategies against MRSA, strep, anthrax, and other pathogens. 
Professor 
Laboratory of Bacterial Pathogenesis and Immunology 
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Top: National Medal of Science recipient Elaine Fuchs with 
President Barack Obama. 
Above: Microbiologist Vincent Fischetti. 
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Above: Physician-scientists Jean-Laurent Casanova (at 
left) and Sohail Tavazoie, who recently established new 
laboratories at the University. 
Albert Lasker Award recipients Jeffrey Friedman, below, and 
Ralph Steinman, right. Dr. Friedman discovered the appetite­
regulating hormone leptin. Dr. Steinman identified dendritic cells, 
key components of the body's immune system. 
Mary Jeanne Kreek, bottom at center, has been an international 
leader in establishing addiction studies as a vital branch of 
biomedical science. 
Jeffrey M. Friedman, M.D., Ph.D., who received a 201Q Albert Lasker 
Award for his discovery of the obesity gene and the weight-regulating 
hormone leptin. 
Marilyn M. Simpson Professor 
Laboratory of Molecular Genetics 
Director, Starr Center for Human Genetics 
Investigator, Howard Hughes Medical Institute 
Elaine Fuchs, Ph.D., recipient of a National Medal of Science in 2009 
for her innovative research on skin stem cells. 
Rebecca C. Lancefield Professor 
Laboratory of Mammalian Cell Biology and Development 
Investigator, Howard Hughes Medical Institute 
David D. Ho, M.D., who is at the forefront of efforts to develop 
HIV vaccines and other prevention strategies. 
Senior Physician, Irene Diamond Professor 
Scientific Director and Chief Executive Officer, Aaron Diamond AIDS Research Center 
Mary Jeanne Kreek� M.D., a pioneer researcher in addiction 
biology who helped develop methadone maintenance therapy for 
heroin addiction. 
Senior Attending Physician, Patrick E. and Beatrice M. Haggerty Professor 
Laboratory of the Biology of Addictive Diseases 
James G. Krueger, M.D., Ph.D., noted for his discoveries about 
psoriasis, who also heads a major initiative on melanoma. 
Senior Attending Physician, D. Martin Carter Professor 
Laboratory for Investigative Dermatology 
Director, Milstein Medical Research Program 
Michel C. Nussenzweig, M.D., Ph.D., who is designing immuno­
therapies for HIV, cancer, diabetes, and other disorders. 
Senior Physician, Sherman Fairchild Professor 
Laboratory of Molecular Immunology 
Investigator, Howard Hughes Medical Institute 
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Jeffrey V. Ravetch, M.D., Ph.D., who studies immune mechanisms and 
is developing new therapies for autoimmune disorders. 
Theresa and Eugene M. Lang Professor 
Leonard Wagner Laboratory of Molecular Genetics and Immunology 
Charles M. Rice, Ph.D., who is a leading authority on the hepatitis C 
virus, one of the main causes of liver cancer. 
Maurice R. and Corinne P. Greenberg Professor 
Laboratory of Virology and Infectious Disease 
Director, Center for the Study of Hepatitis C 
Agata Smogorzewska, M.D., Ph.D., who uses a hereditary genome 
instability syndrome, Fanconi anemia, as a model for understanding 
the cellular aging process and cancer. 
Assistant Professor 
Laboratory of Genome Maintenance 
Ralph M. Steinman, M.D., who received the 2007 Albert Lasker 
Award for his discovery of the dendritic cell, which is now a focus of 
study in laboratories ·worldwide. 
Senior Physician, Henry G. Kunkel Professor 
Laboratory of Cellular Physiology and Immunology 
Director, Christopher H. Browne Center for Immunology and Immune Diseases 
Sohail Tavazoie, M.D., Ph.D., who studies small molecules that block 
tumor metastasis in an effort to improve cancer diagnosis and treatment. 
Senior Attending Physician, Leon Hess Assistant Professor 
Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology 
Leslie B. Vosshall, Ph.D., whose studies of human olfaction are leading 
to a deeper understanding of neurosensory disorders. 
Robin Chemers Neustein Professor 
Laboratory of Neurogenetics and Behavior 
Investigator, Howard Hughes Medical Institute 
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FROM THE BOARD CHAIR 
I first became involved with The Rockefeller University because of 
the . Hospital. Some years ago my daughter was seen by Rockefeller 
doctors. She suffered from psoriasis-not a life-threatening condition 
but decidedly a quality-of-life-threatening one. At the time, I knew little 
about the University. I observed that she received excellent 
care. In return, my family had the satisfaction of knowing 
that her participation was contributing to research that 
might one day provide a cure. 
Above: Board Chair 
Russell Carson with 
Professor Leslie Vosshall. 
My curiosity aroused, I began attending events at the University to 
find out more about it. What I learned so impressed me that I eagerly 
accepted an invitation to join the Board in 1994. In the years since, as 
my knowledge has deepened, so has my appreciation-indeed, my awe­
of the University and its remarkable team of scientists and physicians. 
Their contributions to medical science have been profound. 
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Russell L. Carson 
Chair, The Rockefeller University 
OVERVIEW OF THE ROCKEFELLER UNIVERSITY 
Scientifically and geographically, The Rockefeller University Hospital 
stands at the heart of a world-renowned center for biomedical investi­
gation and graduate education. The Rockefeller University is dedicated 
to research that will improve the understanding of life for the benefit 
of humanity. 
Founded in 1901 as The Rockefeller Institute for Medical Research, the 
University was the nation's first institution devoted exclusively to bio­
medical science. It was renamed The Rockefeller University in 1965. 
A Community of Scholars 
Today, the University comprises more than 70 independent laborato­
ries. The Rockefeller community includes 300 research and clinical 
scientists, 350 postdoctoral investigators, 200 graduate students, 
and 1,050 technical and administrative personnel, all working at the 
University's 14-acre campus. 
A Unique Open Structure 
Since its founding, The Rockefeller University has embraced an open 
structure to encourage collaborations between disciplines and empower 
faculty members to take on high-risk, high-reward projects. No formal 
departments exist, bureaucracy is kept to a minimum, and scientists 
are given resources, support, and unparalleled freedom to follow their 
research wherever it leads. 
Areas of Investigation 
Rockefeller's scientists conduct research in six broad areas: biochemistry 
and structural biology; molecular, cell, and developmental biology; 
medical sciences and human genetics; immunology, microbiology, and 
virology; neuroscience; and physics and mathematical biology. In 
addition, eight interdisciplinary centers focus on Alzheimer's disease, 
cancer, hepatitis C, and other biomedical concerns. 
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Award-Winning Science 
Rockefeller University's unique approach has led to some of the world's 
most revolutionary contributions in biology and medicine. Over the 
years, 23 Nobel laureates have been associated with Rockefeller, includ­
ing two alumni. In addition, the University has been home to 21 recipi­
ents of the Albert Lasker Medical Research Award, 14 National Medal 
of Science recipients, and 14 Gairdner Foundation International award­
ees. Thirty-five members of the current faculty have been elected to the 
National Academy of Sciences. 
An Exceptional Place to Learn 
More than 1,000 scientists have received Rockefeller Ph.D. degrees 
since the graduate program began in 1955. Providing opportunities to 
conduct the highest quality science, the program attracts exceptional 
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students from around the world. The Rockefeller University also 
sponsors one of the nation's top M.D.-Ph.D. programs with neighbor­
ing Memorial Sloan-Kettering Cancer Center and Weill Cornell 
Medical College. In addition, at any 
one time, several hundred postdoctoral 
investigators receive advanced training 
and conduct research in Rockefeller's 
laboratories. 
Funding for New Science 
At Rockefeller, the research enterprise 
and educational programs are support­
ed by government and private grants 
and contracts, private philanthropy, 
and income from the endowment. The 
University's annual operating budget 
totals more than $310 million. 
Key Partnerships 
Rockefeller has close ties to Memorial 
Sloan-Kettering Cancer Center, Weill 
Cornell Medical College, New York­
Presby terian Hospital, and other lead­
ing institutions. In addition, 14 Univer­
sity scientists are Howard Hughes 
Medical Institute Investigators-the 
highest percentage of HHMI Investi­
gators on any biomedical faculty in the 
country. Rockefeller also forges col­
laborations with biotech and pharma­
ceutical companies to speed research 
findings into development and improve 
patient care. 
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Rockefeller University Trustee Judith Roth Berkowitz, 
a member of the Board's Hospital Committee, with 
Physician-in-Chief Barry Coller. 
For more information, please contact: 
Ms. Kate Kadoun 
Senior Director, Outreach Initiatives 
The Rockefeller University 
1230 York Avenue 
New York, NY 10065 
Phone: (212) 327-8694 
E-mail: kadoun@rockefeller.edu 
Web address: www.rockefeller.edu 

